drugset / Trial / NCT02179359
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.
Timeline
- Start
- 2014-09-02
- Primary completion
- 2024-11-21
- Completion
- 2024-11-21
Outcome
Outcome not reported
Stopped: “Replaced by another study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | — |
| Subject | Alemtuzumab | Monoclonal antibody | — | — |
| Subject | Busulfan | Small molecule | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Fludarabine | Small molecule | — | — |